Investigation of Potential Drug-Drug Interactions between Peficitinib (ASP015K) and Methotrexate in Patients with Rheumatoid Arthritis.

ABSTRACT:

Background

Methotrexate is frequently used to treat rheumatoid arthritis. Peficitinib (ASP015K; Smyraf^®), an oral Janus kinase inhibitor indicated for the treatment of rheumatoid arthritis, may be coadministered with methotrexate.

Objective

The objective of this study was to investigate potential drug-drug interactions of peficitinib with methotrexate and the short-term safety of coadministration.

Patients and methods

This phase I, open-label, single-sequence study included patients with rheumatoid arthritis taking a stable dose of methotrexate. Patients received their prescribed methotrexate dose (Day 1) and then peficitinib (100 mg) twice daily from Day 3 until the morning of Day 9; a second methotrexate dose was coadministered with peficitinib on Day 8.

SUBMITTER: Zhu T 

PROVIDER: S-EPMC7452880 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature